semaglutide cardiovascular outcomes 2025 news Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial Cardiovascular risk reduction with once-weekly

For patients preferring oral semaglutide, PlexusDx offers this option at $289/mo (or $249/mo on the 6-month plan) with the same flat-pricing guarantee

The decreased abundance of SCFA-producing bacteria in the gut caused by antibiotic administration has also been associated with enhancing pathogenic colonisation, including by the fungal species Candida albicans known to modulate the permeability and integrity of the gut barrier during infection (Allert et al

The safest approach is to keep it occasional, not a daily habit

The short answer GLP-1 medications (and dual GLP-1/GIP medications like tirzepatide) act on far more than your stomach